Pocket ProgramPlease Join Us for a Co-sponsored Morning Seminar Hosted by
Otsuka Pharmaceutical Development & Commercialization, Inc.

UNDERSTANDING NEUROPLASTICITY IN THE

Treatment of Depression and thePotential Role of Digital Therapeutics
Friday, May 24, 2024 • 8:15–9:15 am
Tokyo International Forum
Floor 7, Room 2, Hall B7 (1)Breakfast will be provided
Altered connectivity between the limbic system, prefrontal cortex, and other areas of the brain
underlies specific symptoms of depression, highlighting the dysfunction of the cognitive andemotional neurocircuits that is evident in depression. Normalization of neurocircuit dysfunction
and neuroplastic changes have been observed with various treatment modalities.
In this program, Dr Atsuo Nakagawa and Dr Craig Chepke will explore the potential to leverage
neuroplasticity as a treatment target for depression and the potential role of digital therapeutics
for mental health.

Atsuo Nakagawa, MD, PhD

Craig Chepke, MD, DFAPA

Chair

Adjunct Associate Professor of
Psychiatry, Atrium HealthProfessor, Department of
Neuropsychiatry

Medical Director, Excel Psychiatric
Associates

St. Marianna University Schoolof Medicine

Scientific Director, Psych Congress

Kawasaki, Japan© 2024 Otsuka Pharmaceutical Development & Commercialization, Inc.

Huntersville, North Carolina

All rights reserved.

April 2024

JP.UNB.X.24.00008

How does cognitive
impairment affect yourpatients with schizophrenia?
Join us at our sponsored
symposium to explore theimpact of cognitive impairment
on patients with schizophrenia.

Friday 24th May,
15:00 – 16:00
Room 2(Hall B7(1))

SC-CRP-15393/SC-JP-05615. May 2024.

CINP2024
Contents- Greeting Message for CINP 2024 .....................2- CINP2024 Organizing Committee .....................4- Information for Participants ...............................5- Information for Chairpersons and Speakers .... 11- Floor Map ........................................................13- Program at a Glance........................................17- Program
Scientific Program............................................28
Industry Academic Collaborative Program .......70- Award Recipients .............................................92- Acknowledgment .............................................93

Greeting Message for CINP 2024

Prof. Joseph Zohar
CINP President

It’s a great honour for me to welcome you to this CINP 35th annual
congress.
When I came to Japan for one of my first CINP meetings in 1990, I neverimagined I would become President, nor have the opportunity of addressing
you in this way. It really is a great privilege for me to congratulate you on
deciding to join us here in Tokyo.
We’ve worked hard to make this meeting scientifically rigorous, incorporating
cutting edge research from acknowledged experts in innovative new formats
like “Meet the Expert” sessions, and are delighted to be introducing our newly
formed Global Networking Communities (GNCs).
The rich social program includes opening and closing ceremonies, a membership reception and early careers evening, a dedicated members’ lounge,
and more. I very much hope to meet you at these events, and particularly
encourage you to attend the General Assembly, where you’ll receive a comprehensive report on CINP’s current and future plans and witness the transition of the presidency to Dr. Ikeda.
I wish you a wonderful meeting, with the perfect blend of science, networking
and sightseeing.
Take care, stay well, and see you at our upcoming meetings in Melbourne,
Australia in 2025 & Glasgow, Scotland in 2026.

2

35th WORLD CONGRESS World Congress CollegiumInternationale Neuro-Psychopharmacologicum

Dr. Kazutaka Ikeda
CINP President-Elect
Local Organizing Committee Chair of CINP2024
Tokyo Congress

I’m thrilled to announce the 35th CINP World Congress of Neuro-Psychopharmacology (CINP2024), taking place at the Tokyo International Forumfrom May 23rd to May 26th. Our theme, “A New Wave of Neuropsychopharmacology Toward Wellbeing,” reflects the exciting progress in our field facilitated by recent scientific and technological advancements.
We’ve seen a surge in the application of neuropsychopharmacology to treat
psychiatric disorders globally. At CINP2024, experts from around the world
will discuss how to develop and improve the use of central nervous system
drugs, paving the way for new breakthroughs.
CINP’s role has become increasingly important as mental health disorders
grow more diverse and prevalent worldwide. This is the second time Japan
has hosted the congress, 34 years after the Kyoto congress in 1990, marking
a significant moment for our country and our global community.
We’re expecting over 2500 experts from 50 countries to join us. The Japanese Society of Neuropsychopharmacology (JSNP) and the JapaneseSociety of Clinical Neuropsychopharmacology (JSCNP) will concurrently
hold their joint annual meeting alongside CINP2024, enriching our congress
further.
I want to sincerely thank you all for your participation and support. Let’s cometogether for fruitful discussions, to forge new friendships, and drive meaningful progress in neuropsychopharmacology.

3

CINP2024 Organizing Committee
Executive Committee
President
Past President
President Elect
Vice President
Vice President
Secretary
Treasurer

Joseph Zohar
Pierre Blier
Kazutaka Ikeda
Dan Rujescu
Maria Oquendo
Gabriella Gobbi
Ming-Chyi Huang

International Scientific Programme Committee (ISPC)
Chair
Pierre Blier
Co-Chair Kazutaka Ikeda
Members Gabriella Gobbi
Joseph Zohar
Alan Frazer
Alessandro Serretti
Allan Young
Atsumi Nitta
Bernhard Baune
Brian Dean
Dan Rujescu
David Morilak
Doo-Sup Choi

George Papakostas Patricio O’Donnell
Giuseppi Fanelli
Reiji Yoshimura
Hiroyuki Uchida
Ryota Hashimoto
Hsien-Yuan Lane
Satoshi Kida
Ike C. dela Pena
Shih-Ku Lin
Julio Licinio
Siegfried Kasper
Kostas Fountoulakis Soraya Seedat
Laura Musazzi
Stefano Comai
Maurizio Popoli
Tomiki Sumiyoshi
Nasser Haddjeri
Ya-Mei Bai
Noboru Hiroi
Yogesh Dwivedi

CINP2024 Local Organizing Committee Members
Chair
Co-Chair
Co-Chair
Chair of JSNP Annual Meeting
Chair of JSCNP Annual Meeting
Secretary
Public Relations Officer
Secretary of JSNP Annual Meeting
Secretary of JSCNP Annual Meeting
Members Ryota Hashimoto
Nobutaka Hattori
Nakao Iwata
Tetsuro Kikuchi

4

Kazutaka Ikeda
Noriko Osumi
Norio Yasui-Furukori
Atsumi Nitta
Koichiro Watanabe
Soichiro Ide
Sotaro Moriyama
Naotaka Izuo
Takashi Tsuboi

Teiji Kimura
Kazutaka Shimoda
Hisatsugu Miyata
Hiroyuki Uchida
Yoshiya Moriguchi Shigeto Yamawaki
Kazuyuki Nakagome Toshikazu Saito

The Gala Dinner Cruise has a limited number of seatsavailable and prior booking was required. At present,
the cruise is at capacity and the registration process
has been closed.
For those who have already are registered, a certificate of participation for the Gala Dinner Cruise isprinted at the bottom of their your entry pass card. If
you cannot see this certificate printed on your card, or
if you have any problems wit your participation or
payment, please visit the Gala Dinner Cruise Enquiry
Desk during the following office hours below. Please
note that after 17 May, we will be unable to respond toemails or telephone enquiries regarding this matterthe cruise.

Floor Map
B1F
D Block 1F

To Plaza 1F
Underground Concourse
相田みつお
美術館

PosterTo Hall E
B2F
Glass Building
1F

To
Plaza 1F

（Lobby Gallery（1）（2））

Exhibition（Lobby Gallery（1）
（2）
）

Lobby
Gallery（2）

相田みつお
美術館

For JR Tokyo Station

For Tokyo Metro Yurakucho Station

B Block 1F B Block 1F

C Block 1F

To Hall E
Lobby
B2F
Gallery（1）Glass
Building
To Hall E
1F
B2F

13

１F

Registration

Registration

JSNP/JSCNP
）

CINP
）

hall D1.5.7

hall B5.7

hall C

Entrance

Entrance

hall A

Entrance

Entrance

B1F

For Tokyo Metro Yurakucho Station

B1F

B1F

2F

2F

B1F

Hall D1

Room4（Hall D1）

To Underground
Concourse
Glass Building
Entrance

Cloak（Cloak（1）
）

Plaza

B1F

To Underground
Concourse&ORDN

Taxi Stand

FORDN  

Glass Building

２F
D Block

C Block

B Block

A Block

Lobby

PC Preview Desk
CINP

JSNP/JSCNP）

Glass Building

14

Glass Building
Entrance

For JR Tokyo Station

B1F

４F

You can go to the "4, 5, 6F" of G Block through the Bridge.

D Block

C Block

B Block

A Block

Room1（Hall C）

Hall C
5F
2F
5F2F

2F

2F5F

Bridge
5F

5F

5F・6F

4F

2F
5F

Room5

5F

G409
Glass Building

G408
G407

（G409）

Room9（G404）

Room6（G408）

Room7

Room10

G Block

G405

Room8

（G407）

G404（G402）

G402（G405）

５F
D Block

Room12

C Block

B Block

A BlockHall
D5
7F 2F 7F

（Hall D5）

Exhibition
Hall B5

4F（Hall B5（1）
（2）
）
4F

4F

Bridge4F

G510

Room17（G510）

CINP Memberʼs Lounge（Hall B5 Lobby）

5F

5F

6F

Glass Building

Local Congress Secretariat（G508）

Room16（G502）

G Block

G502

15

６F

You can go to the "4, 5, 6F" of G Block through the Bridge.

D Block

C Block

B Block

A Block

7F

Room15

Bridge5F

G610（G610）

Glass Building
6F( G601 )6F

Mosque（G601）

G Block
G602

Room14

G601（G602）

７F
D Block

C Block

B Block

A Block

5F 5F

Hall D7
6F

Hall
Hall
B7（2） B7（1）

Room3（Hall D7）

Room11

Room2（Hall B7（2））（Hall B7（1））

LoungeGlass Building

Event

G Block（Lounge）

G701

Room13（G701）

16

LoungeThu, 23 May | Day 1

Program at a GlanceTokyo International Forum

8：00

Room 1
Hall CRoom 11
Hall B7(2)

9：00

10：00

Room16 (G502)
11：00

10:30-12:00 ME1
Room17 (G510)

10:30-12:00 ME2
12：00

13：00

12:30-13:30
CLS1

14：00

13:40-14:30
Opening and Award Ceremony

15：00

14:30-15:30
PL1

16：00

17：00

15:45-17:45
CSS1

18：00

19：00

18:00-19:30
Welcome Reception

English-Japanese Simultaneous Interpretation
17

Fri, 24 May | Day 2
Tokyo International Forum

8：00

Room 1
Hall CRoom 2
Hall B7(1)Room 3
Hall D7

Room 4
Hall D1

Room 5
G409

8:15-9:15

CMS1

9：00

10：00

11：00

9:30-10:30

PL2

10:45-12:00

10:45-12:00

10:45-12:00

10:45-12:00

10:45-12:00

IS1

IS2

IS3

IS4

IS5

12：00

12:15-13:15

14：00

12:15-13:15

CLS2

13：00

CLS3

13:30-14:45

13:30-14:45

13:30-14:45

13:30-14:45

IS6

IS7

IS8

IS9

15:00-16:00

15:00-16:00

SS3

CSS3

13:30-14:30

SS1

15：00

15:00-16:15

15:00-16:00

15:00-16:00

SS6

SS5

JCB

16：00

16:15-17:15
17：00

PL3

18：00

19：00

English-Japanese Simultaneous Interpretation18

Program at a GlanceTokyo International Forum
Room 6
G408

Room 7
G407

Room 8
G405

Room 9G404

Room 10
G402

Poster
Lobby Gallery

8：00

9：00

10：00

10:45-12:00

SC1

10:45-12:00

SC2

10:45-12:10

10:45-12:00

SC3

SC4

11：00

10:45-11:45

AW1
12：00

13：00

13:30-14:30

13:30-14:55

13:30-14:45

13:30-14:45

13:30-14:55

SC5

SC6

SC7

SC8

15:00-16:00

15:00-16:00

15:00-16:00

AW2

FC1

SS4

14：00

SS2

15：00

15:00-15:50

SC9

15:00-16:15

SC10

16：00

17：00

17:30-18:30

Poster

18：00

19：00

19

Sat, 25 May | Day 3
Tokyo International Forum

8：00

Room 1
Hall CRoom 2
Hall B7(1)Room 3
Hall D7

Room 4
Hall D1

Room 5G409

8:00-9:00

CMS2
9：00

9:00-10:00

PL4
10：00

10:10-11:25

10:10-11:25

10:10-11:25

10:10-11:25

10:10-11:25

11：00

IS10

IS11

IS12

IS13

IS14

12：00

11:40-12:40

CLS9

11:40-13:00

CLS10

13：00

13:00-14:15

13:00-14:15

13:00-14:15

13:00-14:15

IS15

IS16

IS17

IS18

14:30-15:30

14:30-15:30

14:30-15:30

SS7

SS8

FC4

13:00-14:00

SS9

14：00

15：00

16：00

14:30-15:30

CSS5
15:40-16:40

PL5
17：00

18：00

19：00

English-Japanese Simultaneous Interpretation
20

14:30-15:45

IS19

Program at a GlanceTokyo International Forum
Room 6
G408

Room 7
G407

Room 8
G405

Room 9G404

Room 10
G402

Poster
Lobby Gallery

8：00

9：00

10：00

10:10-11:25

10:10-11:35

SC11

SC12

10:10-11:10

SC13

10:10-11:25

SC14

10:10-11:10

FC2

11：00

11:40-12:40

12：00

SLS
13：00

13:00-14:00

13:00-14:00

13:00-14:00

SC15

SC16

SC17

14:30-15:10

SC19

13:00-14:15

SC18

13:15-14:15

FC3

14:30-15:30

14:30-15:30

SC20

FC5

14：00

15：00

16：00

16:50-17:50

17：00

Poster
18：00

19：00

21

Sun, 26 May | Day 4
Tokyo International Forum

8：00

Room 1
Hall CRoom 2
Hall B7(1)Room 3
Hall D7

Room 4
Hall D1

Room 5
G409

10:45-12:00

10:45-12:00

IS22

IS23

14:50-15:50

14:50-15:50

SS10

SC24

8:15-9:15

CMS3

9：00

10：00

11：00

9:30-10:30

PL6

10:45-12:00

10:45-12:00

IS20

IS21

10:45-11:45

AW3

12：00

12:15-13:15
13：00

CLS17

14：00

15：00

13:30-15:30

PublicSymposium
14:50-15:50

14:50-16:10

CSS9

FC6

16：00

16:00-17:00

PL7
17：00

18：00

17:30-19:00

Farewell Party
19：00

22

Program at a GlanceTokyo International Forum
Room 6
G408

Room 7
G407

Room 8
G405

Room 9G404

Room 10
G402

Poster
Lobby Gallery

8：00

9：00

10：00

10:45-11:45

10:45-11:45

10:45-11:45

SC21

SC22

SC23

11：00

10:45-12:00

IS24
12：00

13：00

13:30-14:30

Poster
14:50-15:40

SC25

14:50-15:50

14:50-15:40

SC26

SC27

14：00

15：00

16：00

17：00

18：00

19：00

23

Scientific Program- Plenary (PL)- Spotlight Session (SS)- Joint CINP/Brain Symposium (JCB)- WWN/IBRO Luncheon Session (SLS)- Symposium (IS)- Meet the Expert (ME)- Public Symposium (PS)- Award-winners Lecture (AW)- Featured Communications (FC)- Short Communications (SC)- Poster Presentation (PP)May 23rd 14:30 - 15:30

Room 1 (Hall C)

Plenary

PL1 Plenary 1
Chair

Ming-Chyi Huang（Taipei City Psychiatric Center, Taipei
City Hospital）

Alcohol Use Disorder: The Gain in the Brain is in the
Emotional Pain and Implications for Treatment
National Institute on Alcohol Abuse and Alcoholism

George Koob

May 24th 16:15 - 17:15

Room 1 (Hall C)

PL3 Plenary 3
Chair

Pierre Blier（University of Ottawa Institute of Mental HealthResearch）

Cannabis, the Endocannabinoid System, and Mood
Disorders
McGill University

Gabriella Gobbi

PL2→P7028

May 25th 9:00 - 10:00

Room 1 (Hall C)

Plenary

PL4 Plenary 4
Chair

Joseph Zohar（National Post-Trauma Center, Research Foundation by the Sheba Medical Center）

Challenges and Opportunities in Mental Health Research
National Institute of Mental Health

Joshua A. Gordon

May 25th 15:40 - 16:40

Room 1 (Hall C)

PL5 Plenary 5
Chair

Kazutaka Ikeda（Tokyo Metropolitan Institute of Medical
Science）

Brains on fire? The autoimmune basis of severe
mental illness
University of Oxford

Belinda Lennox

29

May 26th 9:30 - 10:30

Room 1 (Hall C)

Plenary

PL6 Plenary 6
Chair

Gabriella Gobbi（McGill University）

The pharmacological treatment of schizophrenia
across the life cycle
Medical University Innsbruck

W. Wolfgang Fleischhacker

May 26th 16:00 - 17:00

Room 1 (Hall C)

PL7 Plenary 7
Chair

Hiroyuki Uchida（Keio University School of Medicine）

Transmission of Misfolded Proteins in Neurodegenerative Disorders: A Common Mechanism of Disease
Progression
University of Pennsylvania

Virginia Man-Yee Lee

30

May 24th 13:30 - 14:30

Room 5 (G409)

SS1 Spotlight Session 1
Neuroscience-based Nomenclature (NbN) and Precision in Psychopharmacology
Chair

Joseph Zohar（National Post-Trauma Center, Research Foundation by the Sheba Medical Center）
University of Ottawa Institute of Mental Health Research

SS1-2

Donald and Barbara Zucker School of Medicine
at Hofstra/Northwell

SS1-3

European Journal of Psychiatric Trainees - Founding
Editor-in-Chief

SS1-4

National Post-Trauma Center, Research Foundationby the Sheba Medical Center

Spotlight
Session

SS1-1

Pierre Blier

Christoph U. Correll

Asilay Seker

Joseph Zohar
May 24th 15:00 - 16:00

Room 10 (G402)

SS4 Spotlight Session 4
TSBPN 2024 Spring Congress
Chairs

Po-See Chen（National Cheng Kung University Hospital）
Chau-Shoun Lee（MacKay Medical College）

Opening Remarks
Institute of Brain Science, National Yang Ming Chiao Tung
University

Ya-Mei Bai
SS2 & 3→P70-71

31

SS4-1 The association between depression duration, theseverity of psychosocial stress, and antidepressantefficacy of prefrontal stimulation in patients withtreatment-resistant depression.
Institute of Brain Science, National Yang Ming Chiao Tung
University

Spotlight
SessionChih-Ming Cheng
SS4-2 The Interplay of Childhood Trauma, Oxytocin, andImpulsivity in Predicting the Onset of Methamphetamine Use.
Taipei Medical University

Kah Kheng Goh
SS4-3 Neurofilament Light Chain As A Potential Indicatorof Delirium Tremens Among Patients with Alcohol
Dependence.
Taipei City Psychiatric Center

Yu-Chi Hou
SS4-4 Minimum effective dose of aripiprazole during main-

tenance for patients in remitted state of psychosis
guided by an exponential tapering method: verification by plasma drug concentration.
National Taiwan University (NTU)

Chun-I Liu
SS4-5 Exploring the Impact of Childhood Neglect on Cog-

nitive Function in Patients with Bipolar Disorder.
Taipei City Psychiatric Center (TCPC)

Yuanzhi Hsueh

Closing Remarks
Cheng Hsin General Hospital

Tung-Ping Su

32

May 24th 15:00 - 16:00

Room 5 (G409)

SS5 Spotlight Session 5
Into a Culture Specific Perspective of Dementia Carein the Philippines: A Joint Symposium of the Philippine Psychiatric Association and Philippine Collegeof Psychopharmacology
Robert D. Buenaventura（University of the East Ramon

Spotlight
Session

Chair

Magsaysay Memorial Medical
Center Inc.）

SS5-1 Current Philippine Demographics
University of the East Ramon Magsaysay Memorial Medical
Center Inc.

Robert D. Buenaventura
SS5-2 Overview of Dementia in the Philippines and The

Use of Locally Validated Assessment Tools
Pampanga Medical Specialist Hospital

Arnold Angelo M. Pineda
SS5-3 APOE, DRD3, BDNF, and COMT Polymorphisms in

Relation to BPSD in a Philippine Population
University of the East Ramon Magsaysay Memorial Medical
Center Inc.

Melissa Paulita Mariano
SS5-4 Diagnosis, Treatment and Prevention Strategies for

Alzheimerʼs Disease
University of Santo Tomas

Encarnita R. Ampil

33

May 24th 15:00 - 16:00

Room 4 (Hall D1)

SS6 Spotlight Session 6
AsCNP 1: Advancing towards a precision medicine
for psychiatry
Chair

Suresh Sundram（Monash University）

Spotlight
Session

SS6-1

Monash University

SS6-2

University of Muenster

SS6-3

Upstate Medical University, SUNY

Suresh Sundram
Bernhard Baune
Julio Licinio
May 25th 14:30 - 15:30

Room 2 (Hall B7(1))

SS7 Spotlight Session 7
Pharmacology and therapeutics of psychedelics
Chair

Gabriella Gobbi（McGill University）

SS7-1

McGill University

SS7-2

IRCCS San Raffaele Hospital

SS7-3

University of Milano-Bicocca

SS7-4

Imaging and Clinical Sciences, G. dʼAnnunzio University

SS7-5

Keio University School of Medicine

Gabriella Gobbi
Danilo De Gregorio
Laura Musazzi
Giovanni Martinotti
Hideaki Tani

34

May 25th 14:30 - 15:30

Room 3 (Hall D7)

SS8 Spotlight Session 8
Bipolar Guideline - 2024 Update - CINP, WPA, and
WFSBP Special Collaboration
ChairsJoseph Zohar（National Post-Trauma Center, Research Foundation by the Sheba Medical Center）

SS8-1

University of British Columbia

SS8-2

University of Ottawa Institute of Mental Health Research

SS8-3

National Post-Trauma Center, Research Foundation by the
Sheba Medical Center

Spotlight
SessionLakshmi Yatham（University of British Columbia）
Lakshmi Yatham
Pierre Blier

Joseph Zohar
May 25th 13:00 - 14:00

Room 5 (G409)

SS9 Spotlight Session 9Introducing CINPʼs Global Networking Communities
Chair

Joseph Zohar（National Post-Trauma Center, Research Foundation by the Sheba Medical Center）

SS9-1 Psychedelic Pharmacology GNC
McGill University

Gabriella Gobbi
SS9-2 Digital Intervention GNC
Lausanne University

Kim Q. Do
SS9-3 Precision Psychiatry GNC
University of Bologna

Alessandro Serretti35

SS9-4 OCD Spectrum GNC
Shanghai Mental Health Center, Shanghai Jiao Tong University
School of Medicine

Zhen Wang
May 26th 14:50 - 15:50

Room 4 (Hall D1)

SS10 Spotlight Session 10
Spotlight
SessionAsCNP 2: The Neuroinflamation Mechanisms andTreatment Targets for Depression.
ChairsTianmei Si（Peking University Sixth Hospital & Peking University Institute of Mental Health）

Hiroyuki Uchida（Keio University School of Medicine）
SS10-1 Simultaneous Modulation of Neuroinflammation,

Oxidative Stress, and NMDAR Dysfunction to Improve Perceived Stress and Cognitive Decline.
Graduate Institute of Biomedical Sciences, China Medical
University

Hsien-Yuan Lane
SS10-2 Clarifying the microglia hypothesis of mood disor-ders using human blood-induced microglia-like(iMG) cells
Graduate School of Medical Sciences, Kyushu University

Takahiro A. Kato
SS10-3 The neuroinflamation mechanisms of MDD, evi-

dences from clinical and preclinical studies.
Peking University Sixth Hospital & Peking University Instituteof Mental Health

Tianmei Si

36

May 24th 15:00 - 16:15

Room 3 (Hall D7)

JCB Joint CINP/Brain Symposium
Joint CINP/Brain Symposium on Difficult to Treat Depression
Chair

Joseph Zohar（National Post-Trauma Center, Research Foundation by the Sheba Medical Center）

JCB-1

University of Ottawa Institute of Mental Health Research

JCB-2

Catholic University of Rio Grande do Sul

JCB-3

McGovern Medical School, The University of Texas Health
Science Center

Pierre Blier
Pedro Do Prado Lima

Joint CINP/Brain WWN/IBRO
Symposium
Luncheon SessionJoão Luciano De Quevedo
May 25th 11:40 - 12:40

Room 10 (G402)

SLS WWN/IBRO Luncheon Session
Empowering Women in Science: Navigating CareerStages and Leadership
Chair

Noriko Osumi（Tohoku University School of Medicine）

SLS-1

National Center for Complementary and Integrative Health

SLS-2

Arts & Sciences at Worcester Polytechnic Institute

SLS-3

The University of Alabama

Emmeline Edwards
Jean King
Minae Niwa

37

May 24th 10:45 - 12:00

Room 1 (Hall C)

IS1 Symposium 1
Risk and Resilience in PTSD: Analyzing Trajectories
and New Treatment Approaches
Chair

Eric Vermetten（Leiden University Medical Center）

IS1-1

Rising to the Challenge: Emerging Approaches andInterventions for PTSD
University of Alberta

Lisa Burback
IS1-2

Trajectories and their risk factors of post-traumaticstress symptoms among the Japan Self-Defense
Force personnel deployed to humanitarian assistance missions.
National Defense Medical College Research Institute

Masanori Nagamine
IS1-3

Lessons learned from the implementation of in person scalable interventions for Ukraineʼs displaced
people in bordering countries (U-RISE project)
Neuro and Developmental Psychology, Vrije Universiteit
Amsterdam

Iryna Frankova
May 24th 10:45 - 12:00

Room 2 (Hall B7(1))

Symposium

IS2 Symposium 2
Time for a serotonin rethink: new discoveries in serotonin neuron heterogeneity
Chair

Yu Ohmura（Chinese Institute for Brain Research）

IS2-1

New discoveries in 5-HT neuron diversity and function through large scale neurophysiological recordings
University of Oxford

Trevor Sharp

38

IS2-2

Serotonergic neurons in the dorsal raphe are activated by emotional salience
Columbia University

Bradley Miller
IS2-3

Contrasting roles of serotonin neurons in the dorsal
and median raphe in positive and negative emotions
Kyoto University

Kazuki Nagayasu
May 24th 10:45 - 12:00

Room 3 (Hall D7)

IS3 Symposium 3
Targeting Autoantibodies: A Precision Medicine Approach in Psychotic Disorders
Chair

Belinda Lennox（University of Oxford）

IS3-1

Prevalence of Serum Auto-Antibodies in Patientswith Psychosis and/or Seizures
University of Southern California

Steven Siegel
IS3-2

Anti-gliadin and anti-EBV antibodies in sever mental
illness
Johns Hopkins School of Medicine

Robert H. Yolken
IS3-3

Symposium

A novel targeted therapy for anti-NMDA receptor
autoantibody-related disorders
Arialys Therapeutics, Inc.

Mitsuyuki Matsumoto

39May 24th 10:45 - 12:00

Room 4 (Hall D1)

IS4 Symposium 4
Targeting neural circuits for therapeutic intervention
in altered salience and reward related psychiatricconditions
Chair

Huai-Hsuan Tseng（National Cheng Kung University）

IS4-1

Alteration of salience and reward processing and(social) cognitive deficits in schizophrenia and bipolar disorder
National Cheng Kung University

Huai-Hsuan Tseng
IS4-2

Neurocognitive mechanisms for jumping to conclusions, cognition/metacognition, and egodisturbance in psychosis/schizophrenia.
Aichi Medical University

Jun Miyata
IS4-3

Altered Resting-State Network in Adolescents with
Problematic Internet Use in Indonesia
Faculty of Medicine, Universitas IndonesiaCiptoMangunkusumo Hospital

Kristiana Siste
May 24th 10:45 - 12:00

Room 5 (G409)

Symposium

IS5 Symposium 5
Optimizing repetitive transcranial magnetic stimulation therapies for depression and addiction: challenges and pitfalls
Chair

Georg S. Kranz（Medical University of Vienna）

IS5-1

Harnessing simultaneous rTMS/fNIRS to optimize
rTMS treatment efficacy
Medical University of Vienna

Georg S. Kranz

40

IS5-2

Targeting cortical plasticity in drug addiction
Shanghai Mental Health Center

Ti-Fei Yuan
IS5-3

Potential of Maintenance Theta Burst Stimulation
Therapy for Preventing Relapse after Acute Theta
Burst Stimulation Therapy Response for Difficult-toTreat Depression: A Real World Case Series
Keio University School of Medicine

Yoshihiro Noda
May 24th 13:30 - 14:45

Room 1 (Hall C)

IS6 Symposium 6
Novel therapies to treat bipolar disorder: translation
and back-translation between preclinical and clinicalstudies
Chair

Michael Berk（Deakin University）

IS6-1

Search for new treatment options of bipolar disorderusing model miceJuntendo University Graduate School of Medicine

Tadafumi Kato
IS6-2

Trimetazidine to treat the brain and the heart in bipolar depression
Deakin University

Jee Hyun Kim

Symposium

IS6-3

Modulating Dopamine Transporter as a therapeutictarget for bipolar disorder
University of British Columbia

Lakshmi N. Yatham

41

May 24th 13:30 - 14:45

Room 2 (Hall B7(1))

IS7 Symposium 7
Decoding Ketamineʼs Enigma: Unravelling the role ofspecific NMDA Receptor Subunits in its antidepressant and cognitive functions.
Chair

Rachel Hill（Monash University）

IS7-1

NMDAR antagonists disrupt hippocampal neuralnetwork firing at baseline and during working memory maintenance to alter working memory performance
Monash University

Rachel Hill
IS7-2

The role of NMDA receptor GluN2D subunit in
GABA neurons on the long-lasting antidepressant effects of ketamine enantiomers and their metabolites
Tokyo Metropolitan Institute of Medical Science

Soichiro Ide
IS7-3

The Role of GluN2A-Containing NMDAR in the Antidepressant Actions of Ketamine.
University of Cyprus

Panos Zanos
May 24th 13:30 - 14:45

Room 3 (Hall D7)

Symposium

IS8 Symposium 8
The impact of early life adversity on brain and behavior
Chair

Zijun Wang（University of Kansas）

IS8-1

Juvenile social isolation affects the development of
excitatory and inhibitory neuronal circuits in medial
prefrontal cortex
Mie Prefectural Mental Medical Center

Hiroki Yoshino

42

IS8-2

Early social isolation stress potentiates heroin seeking by aggravating the dysfunction of prelimbic cortex to ventral tegmental area projection
University of Kansas

Zijun Wang
IS8-3

Early-life stress as risk factor for Alzheimerʼs disease
Swammerdam Institute for Life Sciences, Center for
Neurosciences, Brain plasticity Group University of Amsterdam

Aniko Korosi
May 24th 13:30 - 14:45

Room 4 (Hall D1)

IS9 Symposium 9
Sociability, Motivation and Pleasure in mental disorders: From molecular understanding to therapeuticstrategies.
ChairsMarco A. Riva（University of Milan）
Eri Hashimoto（Sapporo Medical University）

IS9-1

Vulnerability and resilience to prenatal stress exposure in rodents: from neurobiological mechanisms
and circuits to psychopathologic domains.
University of Milan

Marco A. Riva
IS9-2

Disorders of the Social behavior: neuronal circuits
and treatments with psychedelics

Symposium

McGill University

Gabriella Gobbi
IS9-3

New therapeutic approach for treatment of refractory
psychiatric disorders: Recoveries of behavior/
GABAergic interneuron genetic function using drugs
and stem cells
Sapporo Medical University

Wataru Ukai

43

May 25th 10:10 - 11:25

Room 1 (Hall C)

IS10 Symposium 10
The antidepressant effect and mode of action of psilocybin - clinical trial and molecular imaging data fromstudies in man and pig
Chair

Johan Lundberg（Karolinska Institutet）

IS10-1 The clinical effects and adverse effects of psilocy-

bin in Treatment Resistant Depression
Compass pathways

Guy Goodwin
IS10-2 The Relation Between Acute Effects of Altered

State, 5-HT2A Binding and Synaptic Plasticity inLarge Animals and Healthy Control Subjects
Neurobiology Research Unit, Rigshospitalet

Friederike Holze
IS10-3 The antidepressant effect and mode of action of psi-

locybin - clinical trial and molecular imaging datafrom studies in man and animal models
Karolinska Institutet

Johan Lundberg
May 25th 10:10 - 11:25

Room 2 (Hall B7(1))

IS11 Symposium 11
Symposium

Understanding molecular, cellular, and circuit mechanisms and development of therapeutic methods for
PTSD
Chair

Satoshi Kida（The University of Tokyo）

IS11-1 Molecular and Cellular Mechanisms of PTSD andthe development of its improvement method
The University of Tokyo

Satoshi Kida

44

IS11-2 Novel amygdala mechanisms mediating fear and po-

tential targets for drug treatment
NIH

Andrew Holmes
IS11-3 Prefrontal encoding of an internal model for emo-

tional inference
RIKEN Center for Brain Science

Joshua Johansen
May 25th 10:10 - 11:25

Room 3 (Hall D7)

IS12 Symposium 12
Digital phenotype to guide clinical interventions for
suicide treatment
Chairs

Enrique Baca-Garcia（Fundacion Jimenez Diaz. Universidad
Autonoma de Madrid）

Fuensanta Aroca（Universidad Nacional Autónoma de Mexico）

IS12-1 Smartcrisis 3.0: Use the EMA Suicide Behiovior

Data in Real Time to Treat Suicide Behaviour
Hospital General Universitario Gregorio Marañon

Maria Luisa Barrigon
IS12-2 Phenotyping suicidal behaviour what could we learn

from digital studies ?
University of Montpellier

Symposium

Philipe Courtet
IS12-3 Digital phenotyping of stress responsive suicidal

ideation in healthy individuals: an opportunity forprevention
Perelman School of Medicine, University of Pennsylvania

Maria A. Oquendo45

May 25th 10:10 - 11:25

Room 4 (Hall D1)

IS13 Symposium 13
Improving Outcomes in Mental Illness: From Neuroimaging and Digital Technology to Implementation
Science
ChairJohn M. Kane（Donald and Barbara Zucker School of Medicine at Hofstra/Northwell）

IS13-1 The neurobiological correlates of treatment re-sponse following the first psychotic episode: theneed for new approaches
Donald and Barbara Zucker School of Medicine
at Hofstra/Northwell

Jose M. Rubio
IS13-2 Exploring Wearables and Machine Learning for De-

pression Screening and Monitoring
Keio University School of Medicine

Taishiro Kishimoto
IS13-3 The underutilization of LAIs and clozapine: The roleof implementation science
Donald and Barbara Zucker School of Medicine
at Hofstra/Northwell

John M. Kane
May 25th 10:10 - 11:25

Room 5 (G409)

Symposium

IS14 Symposium 14
Understanding the Mechanisms of Social Stress andAutism-linked Social Deficits
Chair

Zhen Yan（State University of New York at Buffalo）

IS14-1 Circuitry and Molecular Mechanisms of Mental Dis-turbance by Chronic Social Isolation StressState University of New York at Buffalo

Zhen Yan

46

IS14-2 Brain-Periphery Interplay of Inflammation in Social

Defeat Stress
Kobe University Graduate School of Medicine

Tomoyuki Furuyashiki
IS14-3 NMDA receptor dysfunction in mouse models ofautism spectrum disorders
Institute for Basic Science

Eunjoon Kim
May 25th 13:00 - 14:15

Room 1 (Hall C)

IS15 Symposium 15
New Insights on Cannabis Use and Clinical Implications: Translational Perspective
Chair

Deepak DʼSouza（Yale University）

IS15-1 Effects of cannabinoids and antipsychotics on thelipidome in healthy volunteers
The University of Sydney

F. Markus Leweke
IS15-2 In Vivo Imaging of Translocator Protein in Long-term

Cannabis Users and Astrocytes in early Psychosis
McGill University

Romina Mizrahi
IS15-3 Delta-9-tetrahydrocannabinol Modulates Immuno-

Symposium

genomic Function at Single Cell Resolution
Yale School of Medicine

Ke Xu

47

May 25th 13:00 - 14:15

Room 2 (Hall B7(1))

IS16 Symposium 16
Targeting Neurotransmitter Systems in Addiction:
Advances and Future Directions
Chair

Kazutaka Ikeda（Tokyo Metropolitan Institute of Medical
Science）

IS16-1 Beyond dopamine: GABA signaling in cue-reward

learning
Yale University

Marina Picciotto
IS16-2 Neuropsychopharmacological factors that influencedrug choice
CNRS, University of BordeauxSerge H. Ahmed
IS16-3 G-Protein-Activated Inwardly Rectifying Potassium(GIRK) Channels: A Potential Therapeutic Frontier
for Addiction
Tokyo Metropolitan Institute of Medical Science

Kazutaka Ikeda
May 25th 13:00 - 14:15

Room 3 (Hall D7)

IS17 Symposium 17
Symposium

Identifying and fixing dysfunctional circuits in depression: leveraging systems neuroscience andtranslational approaches for developing novel targets and therapeutics.
Chair

Satoshi Kida（University of Tokyo）

IS17-1 Neural signatures of stress susceptibility and resil-

ience in the amygdala-hippocampal network
UCSF

Mazen Kheirbek

48

IS17-2 Targeting Basal Ganglia Circuitry for the Treatmentof Major Depressive Disorder
MapLight Therapeutics

Anatol Kreitzer
IS17-3 The prelimbic cortex dynamically controls and en-hances fear representation in mice.
ESPCI PSL Paris

Gisella Vetere
May 25th 13:00 - 14:15

Room 4 (Hall D1)

IS18 Symposium 18
Sex differences in psychiatric disorders: from molecular neurobiology to therapeutic strategies
Chair

Marin Veldic（Mayo Clinic）

IS18-1 Ovarian hormones and early-life stress alter tran-

scriptional regulation in the nucleus accumbens resulting in sex-specific responses to cocaine
Fordham University

Marija Kundakovic
IS18-2 Sex differences in neural mechanisms of negative

cognitive bias, a cognitive symptom of depression
University of Toronto, Centre for Addiction and Mental HealthSymposium

Liisa Galea
IS18-3 Sex differences in the brain and cognition in schizo-

phrenia
University of Miyazaki

Yoji Hirano

49

May 25th 14:30 - 15:45

Room 5 (G409)

IS19 Symposium 19
Predicting and quantifying treatment response todrugs for psychosis and symptom severity in schizophrenia using machine learning
Chair

Søren Dinesen Østergaard（Aarhus University Hospital）

IS19-1 Predicting Treatment Outcomes in Trials of Drugs

for Psychosis Using Symptom-level Data
Institute of Neuroscience and Physiology, University ofGothenburg

Fredrik Hieronymus
IS19-2 Prediction of clozapine treatment among patientswith schizophrenia via routinely collected data fromelectronic health records
Aarhus University Hospital

Søren Dinesen Østergaard
IS19-3 Quantification of psychiatric symptoms using natural

language processing: preliminary results from a large
conversational corpus of Japanese patients
Keio University School of Medicine

Taishiro Kishimoto

Symposium
50May 26th 10:45 - 12:00

Room 1 (Hall C)

IS20 Symposium 20
Dysfunction of Glutamate, Dopamine, and GABA
Neurotransmission in Schizophrenia: Integrative
View for Pathophysiologic Analysis and Innovative
Treatment
Chair

Toru Nishikawa（Showa University School of Medicine）

IS20-1 Interrelationships among dysregulation of NMDA re-

ceptor, D-serin signaling, dopamine and GABA neurotransmission in schizophrenia: Implication fortreatment development strategy
Showa University School of Medicine

Toru Nishikawa
IS20-2 The Centrality of the Glutamatergic Synapse in the

Pathophysiology of Schizophrenia
Harvard University

Joseph T. Coyle
IS20-3 Neurocognition and NMDAR Co-agonists Pathways

in Individuals with Treatment Resistant FirstEpisode Psychosis
Center for Psychiatric Neuroscience, Lausanne University
Hospital

Kim Q. Do

Symposium
51

May 26th 10:45 - 12:00

Room 2 (Hall B7(1))

IS21 Symposium 21
Late-Life Treatment Resistant Depression: Advances in pharmacotherapy, brain stimulation, andbrain-based mechanisms of treatment response variability.
Chair

Jordan F. Karp（Tucson, University of Arizona）

IS21-1 Augmentation Vs. Switch Approaches for Treatment-

Resistant Depression in Older Adults: Methods andMain Results From the Optimum Study and Considerations for Ketamine in Late-Life.
Tucson, University of Arizona

Jordan F. Karp
IS21-2 Predictors of remission after repetitive transcranial

magnetic stimulation for the treatment of late-life depression: a FOUR-D trial report
Centre for Addiction and Mental HealthDaniel Blumberger
IS21-3 Brain-based mechanisms of treatment response vari-ability in late-life depression
Center for Preventive Medicine, Keio University

Masaru Mimura

Symposium
52

May 26th 10:45 - 12:00

Room 4 (Hall D1)

IS22 Symposium 22
Multi-modal Approaches to Identify Novel
Mitochondria-Based Strategies to the Diagnosis andTreatment Mood Disorders
Chair

Hilary P. Blumberg（Yale School of Medicine）

IS22-1 Novel multi-modal neuroimaging approaches to un-cover mitochondrial mechanisms underlying brain
circuitry dysfunction in bipolar disorder
Yale School of Medicine

Hilary P. Blumberg
IS22-2 Defining a Subtype of bipolar disorder with mito-

chondrial dysfunctions by genomic stratification toward new therapeutic opportunities
Juntendo University

Masaki Nishioka
IS22-3 Unlocking the potential of mitochondrial blood-based patient stratification for bipolar disorder anddepression: towards tailored treatment approaches
University of Toronto

Ana Cristina Andreazza
May 26th 10:45 - 12:00

Room 5 (G409)

Symposium

IS23 Symposium 23
Multi-omics approaches to understand the biologicalmechanisms of mood disorders
Chair

Niamh Mullins（Icahn School of Medicine at Mount Sinai）

IS23-1 Fine-mapping genomic loci refines bipolar disorderrisk genes
Icahn School of Medicine at Mount Sinai

Niamh Mullins

53

IS23-2 Single-cell genomic studies in major depressive dis-order
McGill University

Gustavo Turecki
IS23-3 Detection of mitochondrial dysfunction in six brain

regions including the paraventricular thalamic nucleus of patients with bipolar disorder
Juntendo University Graduate School of Medicine

Mie Kubota-Sakashita
May 26th 10:45 - 12:00

Room 10 (G402)

IS24 Symposium 24
Cognitive Inflexibility: Transdiagnostic Clinical Syndromes, Endophenotype, and Response to Neurostimulation and Pharmacological Treatment
Chair

Eric Hollander（Albert Einstein College of Medicine）

IS24-1 Cognitive Inflexibility; Diverse Health and Wellbeing

Harms Indicate The Need For New Clinical and Public Health Approaches
University of Hertfordshire

Naomi Fineberg
IS24-2 Cognitive Inflexibility in Autism Spectrum Disorderand Related Developmental Disorders
Albert Einstein College of Medicine

Symposium

Eric Hollander
IS24-3 The role of cognitive inflexibility in anxiety, mooddisorders and ADHD
McMaster University

Michael Van Ameringen

54

May 23rd 10:30 - 12:00

Room 16 (G502)

ME1 Meet the Expert 1
Meet the Experts on Obsessive and Compulsive Disorders
Experts Joseph Zohar（National Post-Trauma Center）
Zhen Wang（Shanghai Mental Health Center）
Tomohiro Nakao（Graduate School of Medical Sciences, Kyushu University）

May 23rd 10:30 - 12:00

Room 17 (G510)

ME2 Meet the Expert 2
Meet the Experts on Difficult-to-treat depression
Experts Pierre Blier（University of Ottawa Institute of Mental HealthResearch）
João Luciano De Quevedo（McGovern Medical School, The
University of Texas Health Science Center）
Pedro Schmidt Do Prado Lima（Catholic University of Rio
Grande do Sul）

Meet theExpert55

May 26th 13:30 - 15:30

Room 2 (Hall B7(1))

PublicSymposium

PS Public Symposium
Brain Mechanisms of Addiction and Development ofTreatment Methods
ChairsMiho Terunuma（Niigata University Graduate School of
Medical and Dental Sciences）

Soichiro Ide（Tokyo Metropolitan Institute of Medical Science）

PS-1

Up in smoke: Targets for nicotine in the brain andthe development of nicotine addiction
Yale University

Marina Picciotto
PS-2

Changing the conversation about alcohol
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

George Koob
PS-3

Current and Promising Neuroscience-based Medications to Treat Alcohol Use Disorder
The Scripps Research InstituteBarbara Mason
Second half Session (Only in Japanese)

56

May 24th 10:45 - 11:45

Room 10 (G402)

AW1 Award-winners Lectures 1
Rafaelsen Young Investigators Award
Chair

Kim Q. Do（Lausanne University）

AW1-1 Gender difference of transcranial direct current

Award-winners
Lecturesstimulation (tDCS) plus sodium benzoate for thetreatment of early-phase Alzheimerʼs disease: A randomized, double-blind, placebo-controlled trial
Kaohsiung Chang Gung Memorial Hospital

Chieh-Hsin Lin
AW1-2 Glutamatergic dysfunction in dorsal striatum under-lies compulsive eating in an animal model of binge
eatingUniversity of Melbourne

Robyn Mary Brown
AW1-3 Initial data implicating the use of ketamine as a tar-geted treatment for depression in Parkinsonʼs disease
Yale University

Sophie E. Holmes
May 24th 15:00 - 16:00

Room 8 (G405)

AW2 Award-winners Lectures 2
CINP 2024 Excellent Presentation Award
Chair

Maria Oquendo（University of Pennsylvania）

AW2-1 Effect of daily sunshine hours on SLC6A4 promoter

methylation
Medical University of Vienna

Marie Spies

57

AW2-2 New targets for rapid antidepressant action and po-

tential intervention approaches for stress-related disorders
Peking University

Ying Han
AW2-3 Breaking Good? Repurposing Recreational Drugs toAward-winners
Lectures

Weaken Maladaptive Reward Memories in Heavy
Drinking.
University College London

Ravi Das
AW2-4 Early social isolation stress potentiates heroin seek-

ing by aggravating the dysfunction of prelimbic cortex to ventral tegmental area projection
University of Kansas

Zijun Wang
Presentation on May 26 in FC6
May 26th 10:45 - 11:45

Room 3 (Hall D7)

AW3 Award-winners Lectures 3
CINP Sumitomo Pharma Brain Health Basic & ClinicalResearch Award
Chair

Joseph Zohar（National Post-Trauma Center, Research Foundation by the Sheba Medical Center）

AW3-1

Kobe University

Tomoyuki Furuyashiki
AW3-2

Imaging and Clinical Sciences, G. dʼAnnunzio University

Giovanni Martinotti

58

May 24th 15:00 - 16:00

Room 9 (G404)

FC1 Featured Communications 1
How can medications be used to treat substanceuse disorders, sustain recovery and treat drug overdose?
Chair

Yuki Moriya（Tokyo Metropolitan Institute of Medical Science）

FC1-1 Mitochondrial dysfunction in bone density metabo-lism in patients with opioid use disorder undermethadone maintenance treatment
Changhua Christian Hospital

FeaturedCommunications

WENYU HSU
FC1-2 Insights into the lethal toxicity of synthetic psy-choactive cathinones from studies in larval zebrafish
University of Toledo

Frank Scott Hall
FC1-3 Sex differences in the reduction of hopelessness inµ opioid receptor deficient mice by additive effectsof δ opioid receptor agonists
Tokyo Metropolitan Institute of Medical Science

Yuki MORIYAMay 25th 10:10 - 11:10

Room 10 (G402)

FC2 Featured Communications 2
Chair

Joseph T. Coyle（McLean Hospital and Harvard Medical
School）

FC2-1 SARS-CoV-2-Driven Epidermal Growth Factor Re-

ceptor Signaling and the COVID19-AsscociatedPsychosis/Schizophrenia
School of Pharmaceutical Sciences, Wakayama Medical
University

Hiroyuki Nawa

59

FC2-2 Searching for the magic pills for unmet medical

needs in schizophrenia and other neuropsychiatricdisorders: Learning from a novel DAO inhibitor.
Department of Psychology, National Taiwan University, Taipei,
TaiwanWen-Sung Lai
FC2-3 Multiomic profiling of rapid antidepressant mecha-

nisms in a rat model of depression
University of Milano-Bicocca

Laura Musazzi
May 25th 13:15 - 14:15

Room 10 (G402)

FeaturedCommunications

FC3 Featured Communications 3
New players on monoaminergic field: relevance tomental disorders
Chair

Eliyahu Dremencov（Institute of Molecular Physiology andGenetics, Center of Biosciences, Slovak
Academy of Sciences）

FC3-1 TAAR1 agonists as potential anti-addiction candi-dates: preclinical evidence
University at Buffalo

Jun-Xu Li
FC3-2 Ligands of the delta-opioid receptor and trace amine

associated receptor 1 exert similar effects on
monoaminergic transmission in rats
Center of Biosciences, Slovak Academy of Sciences, Bratislava,
Slovakia

Daniil Grinchii
FC3-3 Putative sex differences in the excitability of beta-

endorphin and neuropeptide-Y-secreting neurons of
the arcuate nucleus
Center of Biosciences, Slovak Academy of Sciences

Eliyahu Dremencov

60

May 25th 14:30 - 15:30

Room 4 (Hall D1)

FC4 Featured Communications 4
Investigation in ageing from multiple aspects among
patients with mental disorders
Chair

Yun-Hsuan Chang（Institute of Gerontology, College of Medicine, National Cheng Kung University）

FC4-1 The aging effect on cognitive functioning and emo-

tional intelligence in patients with bipolar disorders
Institute of Gerontology, College of Medicine, National Cheng
Kung University

FeaturedCommunications

Yun-Hsuan Chang
FC4-2 Relationship between Alcohol -related brain dys-function and brain perfusion SPECT
Teine Keijinkai Medical Center

Tomohiro ShirasakaFC4-3 The age effect upon fNIRS measured brain function

between schizophrenia patients and normal controls
Tsaotun Psychiatric Center

TSUO-HUNG LAN
May 25th 14:30 - 15:30

Room 10 (G402)

FC5 Featured Communications 5
Chair

Marina Picciotto（Yale School of Medicine）

FC5-1 Long-acting injectable antipsychotic use in patientswith bipolar disorder: Findings from REAP-BD study
Linkou Chang Gung Memorial Hospital

Shih-Ku LIN
FC5-2 Sex- and dose-dependent catalase increase and its

contribution to cognitive improvement in a benzoate
dose-finding clinical trial for Alzheimerʼs disease
China Medical University Hospital

Hsien-Yuan Lane61

FC5-3 Adjuvant Cithicoline Against Negative Symptomps

and Interleukin 6 (IL-6) In Schizophrenia Patients
With Receiving Risperidone Treatment
Department of Psychiatry, Universitas Hasanuddin, Makassar,
Indonesia

Andi Jayalangkara TANRAMay 26th 14:50 - 16:10

Room 3 (Hall D7)

FC6 Featured Communications 6
Chair

Stefano Comai（University of Padova）

FC6-1 Modulation of the dopaminergic neurotransmission

by controlling the activity of tyrosine hydroxylase

FeaturedCommunications

School of Life Science and Technology, Tokyo Institute ofTechnology, Yokohama, Japan

Hiroshi Ichinose
FC6-2 α6GABAA receptor-selective positive allostericmodulator as a novel therapy for ADHD: A preclinical study in MK-801-treated juvenile mice
Graduate Institutue of Pharmacology, College of Medicine,National Taiwan University

Lih-Chu Chiou
FC6-3 Decoding the Link among Schizophrenia, Metabolic

Syndrome, and the Serotonin/Melatonin Pathway
using the MK-801 Mouse Model
University of Padua

Stefano Comai

62

Short Communications 1―10

DAY 2 (May 24)

Addiction Disorders 1 - Clinical (1)10:45 - 12:00/Room 6 (G408)
Chair Shih-Ku Lin (Linkou Chang Gung Memorial Hospital)
Bipolar Disorders - ClinicalSC2
10:45 - 12:00/Room 7 (G407)
Chair Ya-Mei Bai (Taipei Veterans General Hospital)
Depression 1 - Clinical (1)SC3
10:45 - 12:10/Room 8 (G405)
Chair Michael Berk (Deakin University)
Preclinical - Others
10:45 - 12:00/Room 9 (G404)
SC4Chair Joshua T. Kantrowitz (NYSPI/Columbia)
Schizophrenia 1 - Clinical (1)SC5
13:30 - 14:55/Room 6 (G408)
Chair Bernhard Baune (University of Münster)Anxiety Disorders and Autism - PreclinicalSC6
13:30 - 14:45/Room 7 (G407)
Chair Andrew Holmes (NIH)
Depression 2 - Clinical (2)SC7
13:30 - 14:45/Room 8 (G405)
Chair Gustavo Turecki (McGill University)
Clinical - Others 1
13:30 - 14:55/Room 9 (G404)
SC8Chair Tomiki Sumiyoshi (National Center of Neurology
and Psychiatry)
Depression 5 - Preclinical (1)SC915:00 - 15:50/Room 6 (G408)
Chair Yogesh Dwivedi (University of Alabama at Birmingham)
SC10 Addiction Disorders 2 and Schizophrenia- Clinical (2)15:00 - 16:15/Room 7 (G407)
Chair Giovanni Martinotti ( G. dʼAnnunzio University ofChieti-Pescara)
SC1

Short
Communications
63

Short Communications 11―20

DAY 3 (May 25)

Addiction Disorders and Anxiety Disorders - Translational
10:10 - 11:25/Room 6 (G408)
Chair Yu-Li Liu (National Health Research Institutes)
SC12 Depression 3 - Clinical (3)10:10 - 11:35/Room 7 (G407)
Chair Lakshmi Yatham (The University of British Columbia)
SC13 Schizophrenia and Pain - Preclinical
10:10 - 11:10/Room 8 (G405)
Chair Rachel Hill (Monash University)
10:10 - 11:25/Room 9 (G404)
SC14 Clinical - Others 2
Chair Yoshiya Moriguchi (Lundbeck Japan K.K.)
SC15 Schizophrenia and Autism - Translational
13:00 - 14:00/Room 6 (G408)
Chair Suresh Sundram (Monash University)
13:00 - 14:00/Room 7 (G407)
SC16 COVID-19 - Clinical
Chair Pierre Blier (University of Ottawa Institute of Mental
Health Research)
SC17 Depression 4 - Clinical (4)13:00 - 14:00/Room 8 (G405)
Chair Takeshi Inoue (Tokyo Medical University)
13:00 - 14:15/Room 9 (G404)
SC18 Others 1
Chair Hiroko Kotajima (Tokyo Metropolitan Institute ofMedical Science)
SC19 Schizophrenia 2 - Clinical (2)14:30 - 15:10/Room 7 (G407)
Chair Toru Nishikawa (Showa Medical University/Kyoto
Prefectural University of Medicine)
SC20 Depression 7 - Translational (1)14:30 - 15:30/Room 8 (G405)
Chair Tadafumi Kato (Juntendo University)
SC11

Short
Communications
64

Short Communications 21―27

DAY 4 (May 26)

Addiction Disorders 3 - Preclinical
10:45 - 11:45/Room 7 (G407)
Chair Anthony A. Grace (International Journal of Neuropsychopharmacology)
SC22 Translational - Others 10:45 - 11:45/Room 8 (G405)
Chair Shinya Kasai (Tokyo Metropolitan Institute of Medical Science)
SC23 Depression 6 - Preclinical (2)10:45 - 11:45/Room 9 (G404)
Chair Nasser Haddjeri (INSERM)
14:50 - 15:50/Room 5 (G409)
SC24 Others 2
Chair Yukio Ago (Hiroshima University)
SC25 Depression 8 - Translational (2)14:50 - 15:40/Room 6 (G408)
Chair Tetsuya Suhara (National Institutes for Quantum
Science and Technology)
SC26 Bipolar Disorders - Translational
14:50 - 15:50/Room 7 (G407)
Chair Kazuki Nagayasu (Kyoto University)
SC27 Schizophrenia 3 - Clinical (3)14:50 - 15:40/Room 8 (G405)
Chair Hidenori Yamasue (Hamamatsu University Schoolof Medicine)
SC21

Short
Communications
65

Poster Presentation PP1-1―PP1-13
DAY 2 (May 24) 17:30 - 18:30
Venue: Poster (Lobby Gallery)

Addiction Disorders 1 - Clinical (1)P001 - P017, P401
P018 - P020
PP1-2 Addiction Disorders 2 - Translational
P021 - P029
PP1-3 Addiction Disorders 3 - Others
P030, P031, P033 - P045
PP1-4 Anxiety Disorders
P046 - P052
PP1-5 Attention Deficit Disorders
P053 - P067, P364
PP1-6 Bipolar Disorders (1)P068 - P083
PP1-7 COVID-19
P084 - P105
PP1-8 Depression 1 - Clinical (1)PP1-9 Depression 2 - Preclinical (1)P106 - P117, P119 - P121
P122 - P128
PP1-10 Epilepsy
P129 - P151, P256
PP1-11 Schizophrenia 1 - Clinical (1)P152 - P165
PP1-12 Schizophrenia 2 -PreclinicalP166 - P181
PP1-13 Clinical - Others (1)PP1-1

Poster Presentation PP2-1―PP2-15
DAY 3 (May 25) 16:50 - 17:50
Venue: Poster (Lobby Gallery)

Depression 3 - Clinical (2)P182 - P201
Depression 4 - Preclinical (2)P202 - P219, P118
P220 - P231
PP2-3 Dementia 1 - ClinicalP232 - P237
PP2-4 Translational - Others
P238 - P245
PP2-5 Post-Traumatic Stress Disorders
PP2-6 Schizophrenia 3 - Clinical (2)P246 - P255, P257 - P267, P498
P268 - P273
PP2-7 Schizophrenia 4 - Translational
P274 - P275
PP2-8 Eating Disorders
P276 - P284
PP2-9 Pain
P285 - P300
PP2-10 Sleep Disorders
PP2-1

PosterPresentation

PP2-2

66

PP2-11 Suicide
PP2-12 Autism
PP2-13 Clinical - Others (2)PP2-14 Preclinical - Others (1)PP2-15 Others (1)P301 - P308
P309 - P326
P327 - P335, P032
P336 - P348, P531
P349 - P362, P461, P463

Poster Presentation PP3-1―PP3-14
DAY 4 (May 26) 13:30 - 14:30
Venue: Poster (Lobby Gallery)

Bipolar Disorders (2)P363, P365 - P377
Dementia 2 - Preclinical and others
P378 - P391
PP3-3 Addiction Disorders 4 - Clinical (2)P392 - P400, P402 - P410
P411 - P423
PP3-4 Addiction Disorders 5 - PreclinicalP424 - P447
PP3-5 Depression 5 - Clinical (3)P448 - P459
PP3-6 Depression 6 - Translational
P460, P462, P464 - P467
PP3-7 Depression 7 - Others
P468 - P483
PP3-8 Obsessive-Compulsive Disorders
P484 - P495
PP3-9 Childhood & Adolescent Disorders
PP3-10 Schizophrenia 5 - Clinical (3)P496, P497, P499 - P517
P518 - P521
PP3-11 Schizophrenia 6 - Others
P522 - P525
PP3-12 Personality Disorders
P526 - P530, P532 - P537
PP3-13 Preclinical - Others (2)P538 - P545
PP3-14 Others (2)
PP3-1
PP3-2

PosterPresentation
67Industry Academic Collaborative Program- Plenary 2 (PL2)- Spotlight Session 2 & 3 (SS2 & SS3)
- Co-sponsored Morning Seminar (CMS)- Co-sponsored Luncheon Seminar (CLS)- Co-sponsored Symposium (CSS)May 24th 9:30 - 10:30

Room 1 (Hall C)

Spotlight
Session

PL2 Plenary 2
Chair

Dan Rujescu（Medical University of Vienna）

Spirit of Drug Discovery
Eisai Co., Ltd.

Haruo Naito

May 24th 13:30 - 14:30

Room 10 (G402)

SS2 Spotlight Session 2
Panel discussion with industry leaders
Chair

Suresh Sundram（Monash University）

SS2-1

Worldwide vice present, Janssen

SS2-2

Senior Vice President, Head of Global Medical Affairs,
H. Lundbeck A/S

SS2-3

Head of Medicine Therapeutic Area CNS, Retinopathies andEmerging Markets, Boehringer Ingelheim PharmaGmbH & Co. KG

SS2-4

Senior Vice President, Chief Medical Officer, Neurology Medical
Affairs Executive, DHBL & Medical Affairs, Global AD Office,Eisai Inc.

Peter Fang

Vaidrius Navikas

Christoph von der Goltz

Plenary

Harald Hampel

70

May 24th 15:00 - 16:00

Room 1 (Hall C)

Spotlight
Session

SS3 Spotlight Session 3
Recent Topics in Research and Development ofDrugs for Treating Neuropsychiatric Disorders
ChairsChristoph U. Correll（Donald and Barbara Zucker School of
Medicine at Hofstra/Northwell）

Tetsuro Kikuchi（Otsuka Pharmaceutical）
SS3-1 Exploring Muscarinic Receptors in Schizophrenia: A

Renewed Approach to Developing Innovative Antipsychotics That Go Beyond Dopamine Receptor
Antagonism
Karuna Therapeutics

Ken Kramer
SS3-2 Brexpiprazole: A Review of the New Treatment Ap-

proved for Agitation Associated with Dementia due
to Alzheimerʼs Disease
Otsuka Pharmaceutical Development & Commercialization, Inc.

Malaak BrubakerSS3-3 Exploring Innovative Avenues in the Treatment of Al-

zheimerʼs Disease
Eisai Co., Ltd.

Teiji Kimura

71

May 24th 8:15 - 9:15

Room 2 (Hall B7(1))

CMS1 Co-sponsored Morning Seminar 1
Understanding Neuroplasticity in the Treatment ofDepression and the Potential Role of Digital Therapeutics

Co-sponsoredMorning Seminar

Chair

Atsuo Nakagawa（St. Marianna University School of Medicine）

1

St. Marianna University School of Medicine

2

Excel Psychiatric Associates

Atsuo Nakagawa
Craig Chepke
Co-Sponsored by Otsuka Pharmaceutical Development &Commercialization, Inc.
May 25th 8:00 - 9:00

Room 3 (Hall D7)

CMS2 Co-sponsored Morning Seminar 2
Future Brain Science Research in Japan
ChairsRyosuke Takahashi（Kyoto University）
Tetsushi Kagawa（Japan Agency for Medical Research andDevelopment (AMED)）

Future Brain Science Research in Japan - Perspective from the Core Organization of AMED Brain/
MINDS 2.0
RIKEN CBS

Tomomi Shimogori
Co-Sponsored by Japan Agency for Medical Research andDevelopment (AMED)

72

May 26th 8:15 - 9:15

Room 2 (Hall B7(1))

CMS3 Co-sponsored Morning Seminar 3
Chair

Takeshi Iwatsubo（Department of Neuropathology, Graduate

Co-sponsoredMorning Seminar

School of Medicine, The University of Tokyo National Institute of Neuroscience,
National Center of Neurology and Psychiatry）

Reconsidering therapies based on amyloid pathogenesis of Alzheimerʼs disease
Department of Neurology, Kanazawa University Graduate
School of Medical Sciences

Kenjiro Ono
Co-Sponsored by Eisai Co., Ltd./Biogen Japan Ltd.

73

May 23rd 12:30 - 13:30

Room 1 (Hall C)

CLS1 Co-sponsored Luncheon Seminar 1
A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia
1Duke-NUS Academic Medicine Education Institute2

Medical Affairs, Neuropsychiatry Bristol Myers Squibb

Prakash Masand
Ken Kramer
Co-Sponsored by Bristol Myers Squibb
May 24th 12:15 - 13:15

Room 2 (Hall B7(1))

Co-sponsored
Luncheon Seminar

CLS2 Co-sponsored Luncheon Seminar 2
Chair

!

Hikaru Hori（Faculty of Medicine, Department of Psychiatry,
Fukuoka University）

Current Challenges and Implications of Cognitive
Performance for Clinical Practice in the Treatment ofMajor Depressive Disorder
Department of Psychiatry, University of Münster, Germany

Bernhard Baune
Co-Sponsored by Takeda Pharmaceutical Company Limited/
Lundbeck Japan K.K.
May 24th 12:15 - 13:15

Room 4 (Hall D1)

CLS3 Co-sponsored Luncheon Seminar 3
Chair

Hiroyuki Uchida（Department of Neuropsychiatry, Keio University School of Medicine）

Potential targets for the treatment of depression: The
inflammatory hypothesis.
Department of Neuropsychiatry, Brain and Neurosciences,
Faculty of Medicine Tottori University

Masaaki Iwata
Co-Sponsored by Viatris Pharmaceuticals Japan Inc.
74

May 24th 12:15 - 13:15

Room 12 (Hall D5)

CLS4 Co-sponsored Luncheon Seminar 4* Only in Japanese
Chair

Ken Inada（Kitasato University）

How to proceed in the management of treat resistantdepression -The Possibility of RexultiKansai Medical University

Masaki Kato
Co-Sponsored by Otsuka Pharmaceutical Co., Ltd.
May 24th 12:15 - 13:15

Room 13 (G701)

Co-sponsored
Luncheon Seminar

CLS5 Co-sponsored Luncheon Seminar 5* Only in Japanese

An update on current understanding of tardive dyskinesia: epidemiology, pathology, and burden of patients
Chair

Masaomi Iyo（International University of Health and Welfare

1

Why was tardive dyskinesia turned a blind eye in
psychiatric clinical practice? Learning how to facewith patients with tardive dyskinesia from national
and international database studies

Graduate School）

Department of Neuropsychiatry, Graduate School of Medical
Sciences, Kyushu University

Takahiro A. Kato
2

Impact of Tardive Dyskinesia on Daily Life
Department of Neuropsychiatry, Keio University School of
Medicine

Hiroyoshi Takeuchi
Co-Sponsored by Mitsubishi Tanabe Pharma Corporation/
Janssen Pharmaceutical K.K.

75

May 24th 12:15 - 13:15

Room 14 (G602)

CLS6 Co-sponsored Luncheon Seminar 6* Only in JapaneseRethinking medication for schizophrenia
Chair

Kotaro Hatta（Department of Psychiatry, Juntendo University Nerima Hospital）

1

The pharmacotherapy of schizophrenia based on the
PET studies
Department of Neuropsychiatry, Graduate School of Medicine,
Nippon Medical School

Amane Tateno

Co-sponsored
Luncheon Seminar

2

User friendly psychopharmacotherapy for schizophrenia: Potential role of transdermal antipsychotics
Department of Neuropsychiatry, University of Yamanashi
Faculty of Medicine

Takefumi Suzuki
Co-Sponsored by Sumitomo Pharma Co., Ltd.
May 24th 12:15 - 13:15

Room 15 (G610)

CLS7 Co-sponsored Luncheon Seminar 7* Only in Japanese
Chair

Taishiro Kishimoto（Hills Joint Research Laboratory for Future Preventive Medicine and Wellness,
Keio University School of Medicine）

Perspective of digital biomarker in mood disorders
Department of Neuropsychiatry Graduate Shcool of Medicine
University of the Ryukyus

Yoshikazu Takaesu
Co-Sponsored by Mochida Pharmaceutical Co., Ltd.

76

May 24th 12:15 - 13:15

Room 16 (G502)

CLS8 Co-sponsored Luncheon Seminar 8* Only in Japanese
Chair

Yukio Ago（Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health
Sciences, Hiroshima University）

The New Frontier in Pharmacotherapy for Depression: Moving Beyond the Monoamine Hypothesis
Department of Neuropsychiatry, Kyorin University Faculty of
Medicine

May 25th 11:40 - 12:40

Co-sponsored
Luncheon Seminar

Hitoshi Sakurai
Co-Sponsored by Shionogi & Co.,Ltd.
Room 1 (Hall C)

CLS9 Co-sponsored Luncheon Seminar 9
Chair

Atsushi Iwata（Tokyo Metropolitan Institute for Geriatrics
and Gerontology）

Disease modifying therapies of Alzheimerʼs disease
Department of Neuropathology, Graduate School of Medicine,
The University of Tokyo National Institute of Neuroscience,
National Center of Neurology and Psychiatry

Takeshi Iwatsubo
Co-Sponsored by Eisai Co., Ltd./Biogen Japan Ltd.

77

May 25th 11:40 - 13:00

Room 2 (Hall B7(1))

CLS10 Co-sponsored Luncheon Seminar 10
Challenges and Management of MDD in Working
population and Elderly Patients
Chair

Masaki Kato（Department of Neuropsychiatry, Kansai Medical University, Japan）

1

What is the optimal way to manage MDD in working
individuals?
Department of Neuropsychiatry, Keio University, Japan

Toshiaki Kikuchi
2

Co-sponsored
Luncheon Seminar

What can we learn from patient perspectives to improve our approach to treating emotional blunting in
MDD?
Department of Psychiatry, The University of Hong Kong,
Hong Kong SAR

Michael MC Wong3

How can we best manage MDD in elderly patientswith comorbidities?
Department of Psychiatry, The Catholic University of Korea,
Seoul St. Maryʼs hospital, Republic of Korea

Dong Woo Kang
Co-Sponsored by H. Lundbeck A/S

78

May 25th 11:40 - 12:40

Room 12 (Hall D5)

CLS11 Co-sponsored Luncheon Seminar 11* Only in Japanese
Chair

Takashi Tsuboi（Department of Neuropsychiatry, Kyorin
University School of Medicine）

Master of Guanfacine -Towards ADHD Treatment
Based on Brain PathophysiologyDepartment of Disaster Psychiatry, International ResearchInstitute of Disaster Science,
Tohoku University

May 25th 11:40 - 12:40

Co-sponsored
Luncheon Seminar

Yasuto Kunii
Co-Sponsored by Takeda Pharmaceutical Company Limited.
Room 13 (G701)

CLS12 Co-sponsored Luncheon Seminar 12* Only in Japanese
Chair

Nobutaka Hattori（Department of Neurology, Juntendo University Faculty of Medicine）

Parkinsonʼs disease: The approaches to disease
modification
Department of Neurology, Kanazawa University Graduate
School of Medical Sciences

Kenjiro Ono
Co-Sponsored by Ono Pharmaceutical Co., Ltd.

79

May 25th 11:40 - 12:40

Room 14 (G602)

CLS13 Co-sponsored Luncheon Seminar 13* Only in Japanese
Chair

Tempei Otsubo（Department of Psychiatry, Tokyo Womenʼs
Medical University Adachi Medical Center）

Treatment strategy for major depressive disorder focusing on anxiety symptoms
Department of Neuropsychiatry, Graduate School of Medicine,
University of the Ryukyus

Co-sponsored
Luncheon Seminar

Yoshikazu Takaesu
Co-Sponsored by Viatris Pharmaceuticals Japan Inc.
Medical Affairs
May 25th 11:40 - 12:40

Room 15 (G610)

CLS14 Co-sponsored Luncheon Seminar 14* Only in Japanese
Chair

Nakao Iwata（Department of Psychiatry, Fujita Health University School of Medicine）

Future Challenges for Psychiatric Pharmacotherapy
Tomakomai Midorigaoka Hospital

Ichiro Kusumi
Co-Sponsored by Sumitomo Pharma Co., Ltd.

80

May 25th 11:40 - 12:40

Room 16 (G502)

CLS15 Co-sponsored Luncheon Seminar 15* Only in Japanese
Chair

Ken Inada（Department of Psychiatry, Kitasato University
School of Medicine）

Toward Better Clinical Use of Asenapine - An Overview of the Evidence for Asenapine Department of Neuropsychiatry, Kansai Medical University

Yoshiteru Takekita
Co-Sponsored by Meiji Seika Pharma Co., Ltd.
Room 17 (G510)

Co-sponsored
Luncheon Seminar

May 25th 11:40 - 12:40

CLS16 Co-sponsored Luncheon Seminar 16* Only in Japanese
Chair

Itaru Miura（Fukushima Medical University）

Evidence and prospect for practice of LAI
Yamanashi Prefectural Kita Hospital

Fuminari Misawa
Co-Sponsored by Janssen Pharmaceutical K.K.

81

May 26th 12:15 - 13:15

Room 1 (Hall C)

CLS17 Co-sponsored Luncheon Seminar 17
Chair

Takefumi Suzuki（Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine,
Yamanashi）

State-of-the-art strategies for diagnosing and treating tardive dyskinesia
The Zucker Hillside Hospital, Psychiatry Research, Northwell
HealthCo-sponsored
Luncheon Seminar

John M. Kane
Co-Sponsored by Mitsubishi Tanabe Pharma Corporation/
Janssen Pharmaceutical K.K.
May 26th 12:15 - 13:15

Room 12 (Hall D5)

CLS18 Co-sponsored Luncheon Seminar 18* Only in Japanese
Chair

Ken Inada（Department of Psychiatry, Kitasato University
School of Medicine）

Treatment to cognitive dysfunction in schizophrenia
Department of Psychiatry, Faculty of Medicine, Fukuoka
University

Hikaru Hori
Co-Sponsored by Sumitomo Pharma Co., Ltd. Medical Science82May 26th 12:15 - 13:15

Room 13 (G701)

CLS19 Co-sponsored Luncheon Seminar 19* Only in Japanese
Chair

Yoshikazu Takaesu（Department of Neuropsychiatry,
Graduate School of Medicine, University of the Ryukyus）

Coping with Sleep Disorders: Significance to theMind, Brain, and Body
Pathophysiology of Mental Disorders, Nagoya University
Graduate School of Medicine

May 26th 12:15 - 13:15

Co-sponsored
Luncheon Seminar

Norio Ozaki
Co-Sponsored by Eisai Co., Ltd.
Room 14 (G602)

CLS20 Co-sponsored Luncheon Seminar 20* Only in Japanese
Chair

Hitoshi Sakurai（Department of Neuropsychiatry, Kyorin
University Faculty of Medicine）

The Current Status of Hypnotic Prescribing in Japan, Future Challenges and Prospects
Department of Neuropsychiatry Akita University Graduate
School of Medicine

Masahiro Takeshima
Co-Sponsored by MSD K.K.

83

May 23rd 15:45 - 17:45

Room 1 (Hall C)

CSS1 Co-sponsored Symposium 1!

To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care
ChairsKoichiro Watanabe（Department of Neuropsychiatry, Kyorin
University School of Medicine, Tokyo,
Japan）
Nakao Iwata（Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan）

1

The Significance of Personal Goals in Schizophrenia
Treatment: Unmet Needs, Therapeutic Approaches,
and Recovery Strategies
Psychiatry and Molecular Medicine Zucker School of Medicine
at Hofstra/Northwell, New York, USA
Department of Child and Adolescent Psychiatry Charité
University Medicine, Berlin, Germany

Christoph U Correll

Co-sponsored
Symposium

2

Optimizing Antipsychotic Treatment for Relapse
Prevention and Clinical Recovery in Schizophrenia
Department of Neuropsychiatry, Keio University School of
Medicine, Tokyo, Japan

Hiroyoshi Takeuchi
3

Psychosocial Treatment with a Focus on Recovery
Department of Psychiatry, Hokkaido University Graduate
School of Medicine, Hokkaido, Japan

Naoki Hashimoto
Co-Sponsored by Otsuka Pharmaceutical Co., Ltd.

84

May 24th 10:45 - 12:00

Room 12 (Hall D5)

CSS2 Co-sponsored Symposium 2* Only in Japanese

Strategic Approaches to Achieve Recovery
Chair

Hiroyuki Uchida（Department of Neuropsychiatry,
Keio University School of Medicine）

1

Measurement-Based Care in Major Depressive Disorder 〜From Remission to Functional Recovery〜
Department of Neuropsychiatry, Graduate School of Medicine,
University of the Ryukyus

Yoshikazu Takaesu
2

Challenges to Treatment and Assessment forAchieving Personal Recovery in Patients with Major
Depressive Disorder
Department of Neuropsychiatry,
Kyorin University School of Medicine

May 24th 15:00 - 16:00

Co-sponsored
Symposium

Takashi Tsuboi
Co-Sponsored by
Takeda Pharmaceutical Company Limited, Japan Medical Office/Lundbeck Japan K.K., Medical Affairs
Room 2 (Hall B7(1))

CSS3 Co-sponsored Symposium 3
Cognitive Impairment is a Core Feature of Schizophrenia
ChairsPhilip Harvey（Psychiatry and Behavioral Sciences at the
University of Miami Miller School of Medicine）

Kazuyuki Nakagome（National Center of Neurology and Psychiatry）

1

Cognitive Impairment Associated With Schizophrenia (CIAS) in Japan: Perception and Evaluation
National Center of Neurology and Psychiatry

Kazuyuki Nakagome

85Perception and Evaluation of CIAS Beyond Japan

2

Duke University School of Medicine, Durham, NC, USA

Richard Keefe

How Deficits in Neural Plasticity and Network Function Give Rise to Cognitive Impairment

3

Psychiatry and Behavioral Sciences at the University of Miami
Miller School of Medicine

Philip Harvey
Co-Sponsored by Boehringer Ingelheim International GmbHMay 24th 17:00 - 19:00

Room 16 (G502)

CSS4 Co-sponsored Symposium 4!

Tobacco Harm Reduction - an Update
ChairsRaymond S Niaura（New York University）
Kohji Takada（Department of Psyshiatry, Jikei University

Co-sponsored
Symposium

School of Medicine/Department of Psychology, Teikyo University）
Discussant Naoyuki Hironaka（Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science）

1

Harm reduction - origins, successes and untapped
potential
Global Public Health Network

Katarzyna Kinga Kowalczyk
2

Smoking, safer nicotine products and tobacco harm
reduction - around the world in fifteen minutes
Knowledge Action ChangeDavid MacKintosh
3

Japan tops the world in reducing cigarette sales
Centre for Health Law, Policy & Ethics, University of Ottawa/
Faculty of Law, University of Ottawa/Global LeadershipCouncil, Boston University School of Public HealthDavid T Sweanor

86

Can e-cigarettes help tobacco cigarette smokers
quit? A review of the evidence

4

Departments of Social and Behavioral Sciences, Epidemiology/
Department of Epidemiology, School of Global Public Health,
New York University

Raymond Niaura

Decision-making and habit: understanding maladaptive behaviour from basic animal learning research

5

Department of Psychology, Waseda University

Yutaka Kosaki
Co-Sponsored by Progressive Policy InstituteMay 25th 14:30 - 15:30

Room 1 (Hall C)

CSS5 Co-sponsored Symposium 5!

Which interventions are key to change the trajectoryof schizophrenia?
Chair

Hiroyuki Uchida（Department of Neuropsychiatry School of
Medicine, Keio University）

Co-sponsored
Symposium

The relevance of non-psychotic symptoms in the
management of schizophrenia
Medical University Innsbruck

W. Wolfgang Fleischhacker
Co-Sponsored by Sumitomo Pharma Co., Ltd. Medical Science87May 25th 15:50 - 17:50

Room 14 (G602)

CSS6 Co-sponsored Symposium 6* Only in Japanese

Measurement Based Care in depression
ChairsMasaki Kato（Department of Neuropsychiatry, Kansai Medical University）

Koichiro Watanabe（Department of Neuropsychiatry, Kyorin
University School of Medicine）

1

Measurement Based Care in the Treatment of Depression: Psychotherapeutic Approach to Personal
Recovery
Keio University School of Medicine, Department of
Neuropsychiatry

Toshiaki Kikuchi
2

Evaluation of workers with depression at the time of
return to work

Co-sponsored
Symposium

Department of Psychiatry, Faculty of Medicine, Fukuoka
University

Hikaru Hori
3

About the real Measurement Based Care using IT
devices at psychiatric clinic with using the H-SDS &H-SASIchigaya Himorogi Clinic, Nanko Kokoro no Clinic

Seiji Hongo
Co-Sponsored by Otsuka Pharmaceutical Co., Ltd. Medical Affairs

88

May 25th 15:50 - 17:50

Room 15 (G610)

CSS7 Co-sponsored Symposium 7* No sweets distribution / Only in Japanese

Toward a disease concept integrating substance dependence and behavioral addiction: Consideration ofcommon background from basic and clinical perspectives
ChairsHisatsugu Miyata（Department of Psychiatry, Jikei University School of Medicine/Hirakawa Hospital）
Naoyuki Hironaka（Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science）

1

Development of an animal model to analyze neuralmechanisms of behavioral addiction
Department of Pharmacology, Faculty of Pharmaceutical
Sciences, Hokkaido University

Masabumi Minami

Analysis of addiction using dopamine-related genealtered mice

Co-sponsored
Symposium2

Addictive Substance Project, Tokyo Metropolitan Institute ofMedical Science

Soichiro Ide
3Role of basolateral amygdala in formation of preference to nicotine intake behavior
Department of Pharmaceutical Therapy & Neuropharmacology,
Faculty of Pharmaceutical Sciences, University of Toyama

Atsumi Nitta
4

Smoking Behaviors: Factors and Mechanisms Mediating Transition to Addiction
Department of Psychiatry, Jikei University School of Medicine/
Department of Psychology, Teikyo University

Kohji Takada

89

5

An attempt to create new diagnostic criteria integrating substance dependence and behavioral addiction
Department of Psychiatry, Jikei University School of Medicine/
Hirakawa Hospital

Hisatsugu Miyata
Co-Sponsored by Smoking Research Foundation
May 26th 14:20 - 15:50

Room 12 (Hall D5)

CSS8 Co-sponsored Symposium 8* Only in Japanese

The unmet needs of schizophrenia from various
stakeholdersʼ point of view
ChairsTakahiro Nemoto（Department of Neuropsychiatry,
Toho University School of Medicine）

Satoru Ikezawa（International University of Health and Welfare, IUHW Mita Hospital）

1

Interview to the patient with schizophrenia

Co-sponsored
Symposium

Porque, the Organization of Persons
with Psychosocial Disabilities

Yuhei Yamada
2

Issues for the recovery of patients with schizophrenia〜Employment support facilityʼs point of view〜
job training institution ONE MORE TOYONAKA/
SENRICHUO

Daisuke Haga
3

Interview to the family of the patient with schizophrenia
The National Federation of Associations of Families
with The Mental Illness in Japan

Kumiko Okada

90

4

After overcoming the acute phase of schizophrenia〜Psychiatristʼs point of view〜
Department of Psychiatry, Faculty of Medicine,
Fukuoka University

Hikaru Hori
Co-Sponsored by Medicine Division,
Nippon Boehringer Ingelheim Co., Ltd.
May 26th 14:50 - 15:50

Room 1 (Hall C)

CSS9 Co-sponsored Symposium 9
Chair

Norio Furukori（Dokkyo Medical University, Department of
Psychiatry）

The importance of personalizing long-acting injectables and shared decision-making in schizophrenia
The Donald and Barbara Zucker School of Medicine at Hofstra/
Northwell

Co-sponsored
Symposium

John M. Kane
Co-Sponsored by Janssen Asia Pacific

91

92

Acknowledgment
Premium Sponsors

Platinum

Otsuka Pharmaceutical Co., Ltd.

Sumitomo Pharma Co., Ltd.

H. Lundbeck A/SDiamond

Eisai Co., Ltd.

Ruby

Takeda Pharmaceutical Company Limited

93

Silver

Boehringer Ingelheim International GmbH

Viatris Pharmaceuticals Japan Inc.

Janssen Asia PacificBronzeBristol Myers Squibb

Janssen Pharmaceutical K.K.

Mitsubishi Tanabe Pharma Corporation

Nippon Boehringer Ingelheim Co., Ltd.

Supporter

Otsuka Pharmaceutical Development &Commercialization, Inc.

Smoking Research Foundation

94

Meiji Seika Pharma Co., Ltd.

Ono Pharmaceutical Co., Ltd.
Japan Agency for Medical Research and Development(AMED)

Progressive Policy InstituteCo-sponsored Seminar/Symposium◦Biogen Japan Ltd.
◦Boehringer Ingelheim International
GmbH◦Bristol Myers Squibb◦Eisai Co., Ltd.
◦H. Lundbeck A/S◦Janssen Asia Pacific◦Janssen Pharmaceutical K.K.
◦Japan Agency for Medical Researchand Development (AMED)◦Lundbeck Japan K.K.
◦Meiji Seika Pharma Co., Ltd.
◦Mitsubishi Tanabe Pharma
Corporation◦Mochida Pharmaceutical Co., Ltd.
◦MSD K.K.
◦Nippon Boehringer Ingelheim Co., Ltd.
◦Ono Pharmaceutical Co., Ltd.
◦Otsuka Pharmaceutical Co., Ltd.
◦Otsuka Pharmaceutical Development& Commercialization, Inc.
◦Progressive Policy Institute◦Shionogi & Co., Ltd.
◦Smoking Research Foundation◦Sumitomo Pharma Co., Ltd.
◦Takeda Pharmaceutical Company
Limited◦Viatris Pharmaceuticals Japan Inc.

95

Exhibition◦Nippon Boehringer Ingelheim Co., Ltd.
◦Otsuka Pharmaceutical Co., Ltd.
◦RICOH Company Ltd.
◦RWD Life Science Co., LTD◦STORZ MEDICAL AG◦Sumitomo Pharma Co., Ltd.
◦TEIJIN PHARMA LIMITED◦Viatris Pharmaceuticals Japan Inc.

◦Advanced Animal Model Support◦B & S corporation◦BiPSEE Inc.
◦ECNP - European College of
Neuropsychopharmacology◦ERISA Co., Ltd.
◦H. Lundbeck A/S◦IVIM Technology◦JAPAN BRAIN CORPORATION◦Mitsubishi Tanabe Pharma
Corporation

Advertisement◦AbbVie◦Amgen k.k.
◦Boehringer Ingelheim International
GmbH◦Bristol Myers Squibb◦Cerevel Therapeutics◦Daito Pharmaceutical Co., Ltd.
◦H. Lundbeck A/S◦KYOWA Pharmaceutical Industry Co.,Ltd.
◦NIPPON SHINYAKU CO., LTD.

◦Otsuka Pharmaceutical Co., Ltd.
◦Otsuka Pharmaceutical Development& Commercialization, Inc.
◦School of Pharmacy andPharmaceutical Sciences, Universityof Toyama◦Shionogi & Co., Ltd.
◦Taisho Pharmaceutical Co., Ltd.
◦TEIKOKU SEIYAKU CO., LTD.
◦TOA PHARMACEUTICALS CO., LTD.
◦Viatris Pharmaceuticals Japan Inc.

Award
◦Meiji Seika Pharma Co., Ltd.

◦Sumitomo Pharma Co., Ltd.

Item
◦H. Lundbeck A/S96

Please Join Us for a Non-CME Disease State Educational Theater Sponsored byBristol Myers Squib at CINP2024 • JSNP-JSCNP2024 Joint Meeting

A FOCUSED APPROACH:

Targeting Muscarinic Receptors
in Schizophrenia
Currently approved drugs for schizophrenia have proven useful; however, unmet medical
needs still exist for this patient population. This program will shed light on possible
mechanisms for an innovative class of therapeutics that have shown promisein schizophrenia by targeting muscarinic acetylcholine receptors in the brain.

Thursday, May 23, 2024 | 12:30-1:30 PM JST
Tokyo International Forum | Hall C, Room 1
Lunch will be served

Prakash Masand, MD

Ken Kramer, PhD

Adjunct Professor
Duke-NUS Medical School
Singapore

Vice President, Medical Aﬀairs,
Neuropsychiatry
Bristol Myers Squibb

Dr. Masand is a paid consultant of Bristol Myers Squibb

For more information,please visit medical.karunatx.com
medical.karunatx.com

The personal information you provide when you scan your badge at Bristol Myers Squibb’s symposium includes your name, degree, specialty,
address, email, and NPI number. The purpose of this collection is to calculate the number of visitors to the symposium, and to learn about
your degree and where you are visiting from. Furthermore, we will use your contact information to provide answers to any questions you
may have about Bristol Myers Squibb. If you want to learn more about our privacy practices, visit www.karunatx.com/privacy-policy.
Meal is provided by Bristol Myers Squibb. Bristol Myers Squibb may not provide meals to certain persons at this event. By accepting
a meal at this event, you represent that none of these apply to you: (1) Minnesota or New Jersey provider; (2) healthcare provider
licensed in Vermont; or (3) anyone prohibited from accepting things of value such as food or drink at this event by state or federallaw, or by your employer’s policies. In accordance with the PhRMA Code on Interactions with Health Care Professionals, attendance atthis program is limited to healthcare professionals, therefore attendance by guests or spouses is not permitted. Bristol Myers Squibb
thanks you for your understanding.
The content of this session and the views expressed therein are those of the presenting entity and not of CINP. This session is notpart of the scientiﬁc program and does not provide CME credit.
© 2024 Karuna Therapeutics, Inc., a Bristol Myers Squibb company. MRC-0020 4/24